Insider Buying: Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Buys $13,230.29 in Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You purchased 1,403 shares of the company’s stock in a transaction dated Monday, June 23rd. The shares were acquired at an average price of $9.43 per share, for a total transaction of $13,230.29. Following the purchase, the director now owns 28,000 shares in the company, valued at $264,040. The trade was a 5.28% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Angie You also recently made the following trade(s):

• On Friday, June 20th, Angie You purchased 26,597 shares of Oric Pharmaceuticals stock. The shares were acquired at an average price of $9.39 per share, for a total transaction of $249,745.83.

Oric Pharmaceuticals Trading Down 2.5%

NASDAQ ORIC opened at $10.23 on Thursday. The company has a fifty day simple moving average of $6.93 and a 200 day simple moving average of $7.70. The company has a market cap of $871.80 million, a P/E ratio of -5.47 and a beta of 1.49. Oric Pharmaceuticals, Inc. has a 1 year low of $3.90 and a 1 year high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.09. Equities research analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Institutional Trading of Oric Pharmaceuticals

Several large investors have recently modified their holdings of ORIC. Jane Street Group LLC boosted its holdings in Oric Pharmaceuticals by 56.0% in the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock valued at $174,000 after purchasing an additional 11,198 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Oric Pharmaceuticals by 1,331.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock valued at $2,841,000 after purchasing an additional 473,600 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Oric Pharmaceuticals by 9.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock valued at $1,645,000 after purchasing an additional 24,778 shares during the period. Parkman Healthcare Partners LLC bought a new stake in Oric Pharmaceuticals in the 1st quarter valued at $1,133,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Oric Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock valued at $226,000 after purchasing an additional 3,131 shares during the period. 95.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

ORIC has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of Oric Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Oric Pharmaceuticals in a research note on Monday, May 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Wedbush restated an “outperform” rating and set a $20.00 price target on shares of Oric Pharmaceuticals in a research note on Monday. Finally, Oppenheimer decreased their price objective on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $19.17.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.